RGEN · XBRL financial data

Repligen financial statements, every quarter

The same tables from 15 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RGEN's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cost of goods and services sold	88*	76	77	77	129*	78	91	88	94*	86	94	98
Research and development	10*	11	11	10	12*	13	14	14	13*	14	14	14
Selling, general and administrative	58*	62	65	76	60*	71	71	74	74*	77	77	84
Operating income (loss)	10*	4	5	(8)	(37)*	7	14	17	18*	16	14	(30)
Interest expense	1*	5	5	5	5*	5	5	5	5*	6	6	6
Other income (expense)	7*	(4)	(0)	3	(5)*	(0)	4	(1)	0*	(1)	(0)	2
Income tax expense (benefit)	18*	0	3	(0)	(5)*	2	3	2	6*	(7)	9	12
Net income (loss)	(16)*	3	6	(1)	(34)*	6	15	15	13*	8	5	(38)
Earnings per share, basic USD per share	—	0.06	0.10	(0.01)	—	0.10	0.26	0.27	—	0.15	0.09	(0.68)
Earnings per share, diluted USD per share	—	0.06	0.10	(0.01)	—	0.10	0.26	0.26	—	0.15	0.09	(0.68)
Weighted average shares, basic millions of shares	0*	0	0	0	0*	0	0	0	0*	56	56	57
Weighted average shares, diluted millions of shares	0*	0	0	0	0*	0	0	0	0*	57	57	57

Fiscal quarters (RGEN's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	751	781	809	784	757	697	709	749	566	583	607	727
Marketable securities	—	—	—	—	0	—	—	—	202	202	204	136
Accounts receivable	124	116	123	129	134	147	157	149	159	152	158	151
Inventory	202	198	191	182	143	153	156	160	170	179	187	182
Prepaid and other current assets	34	36	33	36	32	35	35	38	41	46	46	46
Total current assets	1,111	1,131	1,157	1,132	1,066	1,032	1,057	1,096	1,137	1,161	1,201	1,242
Property and equipment, net	207	206	205	203	198	196	193	189	187	173	168	164
Right-of-use asset	116	135	131	127	135	130	128	124	120	114	116	112
Goodwill	987	986	986	988	1,031	1,082	1,114	1,113	1,114	1,107	1,104	1,100
Total assets	2,831	2,854	2,866	2,831	2,830	2,852	2,902	2,924	2,950	2,931	2,950	2,926
Accounts payable	20	19	21	21	32	27	26	29	30	35	33	28
Accrued liabilities	57	59	58	61	62	76	76	77	79	65	77	75
Total current liabilities	165	182	175	108	127	152	123	131	136	126	133	126
Lease liability, non-current	127	145	144	139	146	139	136	132	126	120	121	116
Total liabilities	866	888	882	814	857	867	840	841	844	825	838	835
Retained earnings	433	436	442	441	407	413	428	443	456	465	470	431
Total stockholders' equity	1,965	1,966	1,984	2,017	1,973	1,985	2,062	2,083	2,106	2,105	2,112	2,092
Total liabilities and equity	2,831	2,854	2,866	2,831	2,830	2,852	2,902	2,924	2,950	2,931	2,950	2,926
Common shares outstanding (cover page) millions of shares	56	56	56	56	56	56	56	56	56	56	56	64

Fiscal quarters (RGEN's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(16)*	3	6	(1)	(34)*	6	15	15	13*	8	5	(38)
Stock-based compensation	6*	9	10	23	6*	7	8	9	8*	8	8	9
Net cash from operating activities	29*	45	42*	49*	39*	15	29*	48*	26*	28	33*	43*
Purchases of property and equipment	11*	8	5*	7*	6*	4	7*	5*	8*	5	5*	5*
Net cash from investing activities	(170)*	(8)	(7)*	(6)*	(65)*	(74)	(8)*	(8)*	(209)*	(4)	(2)*	64*
Share repurchases	year only	—	—	—	year only	—	—	—	year only	—	—	—
Net cash from financing activities	268*	(9)	(6)*	(70)*	1*	(5)	(10)*	(0)*	0*	(6)	(6)*	15*
Net change in cash	121*	29	29*	(25)*	(27)*	(60)	12*	40*	(183)*	19	24*	120*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.